Q4 2025 execution reduces worst-case fears. Guide beat is modest but real. Still: sub-peer growth, NIH budget risk, tariff headwinds, and DCF overvaluation prevent higher conviction.
P(above current)=0.5% and DCF FV=$53 vs price $85.88 — model strongly signals overvaluation. Target $92 (+7%) is stale and optimistic. Life sciences instrumentation facing budget tightening across biopharma customers. Cannot hold 5 against this data.
Fair Value Distribution — percentile bands
0.9% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
9.9%/yr
±4.5% · revenue growth to justify current price
FCF-Based Reverse DCF
15.0%/yr
±3.0% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
Q4 2025 beat: revenue M (+6% reported, +4% organic) vs M consensus. 2026 guide: .96-2.99B revenue, adj EPS .35-.45 (beat consensus .32). Biopharma destocking cycle ending; demand returning. But 2-3% o...
RVTY FY2025 reveals slowing growth (4% revenue) against backdrop of tariff headwinds ($25M cost), margin compression (gross margin -104 bps), and inventory/working capital normalization. Life Sciences...